Nextage Therapeutics Ltd (NXTG) - Total Assets
Based on the latest financial reports, Nextage Therapeutics Ltd (NXTG) holds total assets worth ILA353.00K ILA (≈ $946.38 USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nextage Therapeutics Ltd (NXTG) shareholders funds for net asset value and shareholders' equity analysis.
Nextage Therapeutics Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Nextage Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Nextage Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Nextage Therapeutics Ltd's total assets of ILA353.00K consist of 89.8% current assets and 10.2% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0.0% |
| Accounts Receivable | ILA46.00K | 13.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Nextage Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NXTG stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nextage Therapeutics Ltd's current assets represent 89.8% of total assets in 2024, an increase from 26.3% in 2017.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 23.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 72.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.0% of total assets.
Nextage Therapeutics Ltd Competitors by Total Assets
Key competitors of Nextage Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Nextage Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.24 | 2.06 |
| Quick Ratio | 0.05 | 0.24 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA-5.54 Million | ILA-2.84 Million | ILA763.00K |
Nextage Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Nextage Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.45 |
| Latest Market Cap to Assets Ratio | 16.40 |
| Asset Growth Rate (YoY) | -67.8% |
| Total Assets | ILA353.00K |
| Market Capitalization | $5.79 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nextage Therapeutics Ltd's assets at a significant premium (16.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nextage Therapeutics Ltd's assets decreased by 67.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nextage Therapeutics Ltd (2017–2024)
The table below shows the annual total assets of Nextage Therapeutics Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ILA353.00K ≈ $946.38 |
-67.76% |
| 2023-12-31 | ILA1.09 Million ≈ $2.94K |
-27.58% |
| 2022-12-31 | ILA1.51 Million ≈ $4.05K |
-64.61% |
| 2021-12-31 | ILA4.27 Million ≈ $11.45K |
+4.96% |
| 2020-12-31 | ILA4.07 Million ≈ $10.91K |
-32.23% |
| 2019-12-31 | ILA6.01 Million ≈ $16.10K |
+9.68% |
| 2018-12-31 | ILA5.48 Million ≈ $14.68K |
-55.82% |
| 2017-12-31 | ILA12.39 Million ≈ $33.23K |
-- |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.